damage to adjacent structures, thus compounding the impact on vision. Iris defects can also occur without the loss of iris stromal tissue that is characteristic of aniridia. Examples of nonaniridic iris injury include traumatic mydriasis, traumatic iridotomy, and iris pigment epithelial loss.
For decades, iris defects were managed with dark sunglasses, colored or artificial pupil contact lenses, iris suturing, or corneal tattooing. More recently, however, iris prostheses have gained popularity. A 2-piece black iris-reconstruction intraocular lens (IOL) was first used in Germany in 1994 by Sundmacher et al. 1, 2 This device contained a clear poly(methyl methacrylate) (PMMA) IOL with a black PMMA annulus. A modified PMMA capsular tension ring (CTR) was subsequently developed by Volker Rasch, MD, and Kenneth J. Rosenthal, MD, and manufactured by Morcher GmbH. This device has a single black occluder extending radially inward from the ring. This CTR can be inserted through a smaller incision than an iris-reconstruction IOL and placed permanently within the capsular bag.
Morcher iris diaphragms have been implanted in many patients to date. [3] [4] [5] [6] [7] [8] [9] [10] Modifications of the original iris diaphragm IOL include segmental prosthetic irises such as the Morcher 96F used in this study (Figure 1 ), which is a modified CTR with a single black occluder segment extending 90 degrees around the ring. 3, 7, 11, 12 The primary advantage of this modification is that it allows for implantation through a small incision when the capsular bag is intact. Long-term follow-up evaluating the safety and efficacy of these iris prostheses generally has been favorable, 3, 5, 8, [12] [13] [14] 3 ) of the first 13 patients was published in 2008. The current report (report 2) focuses specifically on the safety and efficacy of the Morcher 96F CTR, which is a 0.15 mm thick CTR with a 90-degree segmental occluder manufactured from clinical-quality, ultraviolet light-filtering, opaque PMMA. It is intended for the correction of small sectoral iris defects, although multiple rings can be implanted to cover larger defects, and is designed for implantation in the capsular bag. Data for the 16 patients who had implantation of the 96F model and followed to 1 year are presented.
PATIENTS AND METHODS
The University of California Los Angeles (UCLA) Institutional Review Board (IRB) approved this prospective, single-site, nonrandomized interventional trial in 2002 and has renewed it every year since. The trial was originally approved by the FDA for implantation of 20 patients with various Morcher devices but was expanded after the first 20 were implanted to include 70 patients. Devices implanted in the larger study have included the 96F, 96S, 50D, 50F, and 67B. This study evaluated the safety and efficacy of the 96F modified CTR in eyes with small iris defects that could not be managed satisfactorily by suture techniques because of their size or geometry or because of patient preference for an unsutured approach.
All patients were recruited from the author's (K.M.M.) UCLA practice or referred by other ophthalmologists and optometrists. The same surgeon performed all implantations between 2003 and 2013. Inclusion criteria included age 18 years or older at the time of enrollment, congenital or acquired iris defect with significant light and/or glare sensitivity, contrast loss, blurred vision, and/or multiplopia, aphakia, pseudophakia or the presence of a visually significant cataract in the eye with the iris defect, and willingness to comply with all study protocol requirements. Exclusion criteria included asymptomatic individuals, clear crystalline lenses, iris defects small enough to be closed with sutures, symptoms that could be treated adequately with modified glasses or contact lenses, active ocular infection or inflammation, advanced corneal decompensation, or allergy or intolerance to postoperative medications.
One or 2 Morcher 96F devices were implanted depending on the size of the iris defect. All procedures were performed with simultaneous or antecedent IOL placement in the capsular bag. The CTRs were implanted in the capsular bag and anterior to the IOL in every case. Implantation is contraindicated in the ciliary sulcus space or within a torn capsular bag.
Patients were examined preoperatively and postoperatively at 1 day, 2 weeks, 3 and 6 months, and 1 year. They were seen at other times as needed. All patients continue to be followed beyond the study as regular patients. At each postoperative visit, patients were evaluated for the status of their iris implant and IOL. Safety was evaluated by any decrease in corrected distance visual acuity (CDVA) as well as by adverse events, surgical complications, and secondary surgical interventions. The CDVA was measured on a Snellen chart. Efficacy was evaluated by objective measurement of CDVA with glare and by subjective assessment of daytime and nighttime glare symptoms. The cosmetic appearance of the eye was assessed subjectively. The CDVA with glare was measured in a phoropter or trial lens frame with a transilluminator light held 6 to 12 inches in front and slightly to the side of the study eye in 4 sequential quadrants, recording the lowest visual acuity thus obtained. Daytime and nighttime glare symptoms and cosmesis were scored using a simple rating of 0 (no problem) to 10 (significant problem) preoperatively and 3 months postoperatively. A study coordinator obtained these scores. At the 3-month examination, patients were reminded of their preoperative scores.
The CDVA and CDVA with glare were compared preoperatively with the values 1 year postoperatively with Snellen acuities converted to logMAR values for analysis. Visual acuity of hand motions was converted to 20/20 000, and visual acuity of counting fingers (CF) was converted to 20/400 for the purpose of this study as described by Holladay. 15 Glare symptoms and cosmesis scores were compared preoperatively to 3 months postoperatively. All data analyses were performed using the Wilcoxon signedrank test.
RESULTS
Overall, 16 eyes of 16 patients in the larger Morcher trial were managed with 96F iris diaphragm implantation. Patient demographics, preoperative data, and device information are shown in Table 1 . The patients consisted of 10 men and 6 women ranging in age from 39 to 76 years. Four patients had previous implantation of posterior chamber IOLs and the other 12 had visually significant cataracts. Patient 64, who was pseudophakic, had a significant manifest refractive error at the time of enrollment. He had IOL exchange and implantation of the iris diaphragm device. Ocular trauma was the most common cause of the iris defects in this substudy, with 8 patients suffering from surgical trauma and 6 from penetrating or blunt trauma. Only 2 had congenital iris defects. Both of the congenital patients were afflicted with colobomas of the iris and choroid. The number of devices implanted in each patient depended primarily on the size of the iris defect. Three patients received 2 devices; the rest received 1 device each, for a total of 19 devices.
Case Examples
Three study patients are described in some detail because they demonstrate typical preoperative pathologies and surgical outcomes after iris diaphragm implantation.
Patient 22 was a 61-year-old woman at the time of the modified CTR implantation ( Figure 2 ). She had an iridocyclectomy for an iris spindle-cell melanoma of her right eye. She developed chronic cystoid macular edema (CME) postoperatively and a visually significant cataract. Her CDVA and CDVA with glare before cataract surgery were 20/50
À2 and CF at 10 feet, respectively. Two modified CTRs were implanted because of the size of her iris defect. Three months after surgery, her CDVA and CDVA with glare were 20/20 À2 and 20/40, respectively. About a year after cataract surgery, she had a laser posterior capsulotomy and blepharoptosis repair. Over the next several years, she received injections of bevacizumab and triamcinolone to treat chronic CME. Four years after cataract surgery, she had Ahmed glaucoma tube shunt implantation to treat corticosteroid-induced ocular hypertension.
Patient 10 was a 64-year-old man at the time of CTR implantation ( Figure 3 ). He had scleral buckling, pars plana vitrectomy, and intraocular gas injection for treatment of a macula-on retinal detachment in his right eye. Immediately after surgery, he was found to have an irregularly enlarged pupil. He subsequently developed a visually significant cataract and had cataract surgery with the implantation of a single CTR. His CDVA and CDVA with glare before cataract surgery were 20/400 and 20/125, respectively. Three months after surgery, his CDVA and CDVA with glare were 20/40 À2 and 20/125, and he had a visually significant opacity of the posterior capsule. One year after cataract surgery and 3 months after a laser capsulotomy, his CDVA and CDVA with glare were 20/20 C2 and 20/30, respectively.
Patient 62 was a 43-year-old woman at the time of the modified CTR implantation ( Figure 4 ). She had been highly hyperopic all of her life and had multiple strabismus surgeries as a child. She had a laser iridotomy in both eyes for narrow angle configuration. Cataract surgery in the right eye was complicated by iris prolapse through the phacoemulsification incision, loss of iris pigment epithelium, and postoperative photophobia and glare sensitivity from iris transillumination. Her CDVA and CDVA with glare were 20/15 and 20/30 À2 , respectively, after cataract surgery. She had subsequent surgery to reopen the capsular bag and implant an iris diaphragm. The occluder paddle was aligned with the iris pigment epithelial defect, eliminating the transillumination. A small amount of glare sensitivity remained that could be attributed to posterior capsule opacification (PCO). Her CDVA and CDVA with glare after surgery were 20/15
À2 and 20/15, respectively. A laser posterior capsulotomy was performed 14 months after CTR implantation, resulting in elimination of glare sensitivity.
Several patients had ocular comorbidities that had the potential to negatively affect the final CDVA or predispose to postoperative complications. Three patients had corneal defects, including 1 with a corneal scar after a repaired corneal laceration, 1 with corneal edema, and 1 with a history of Fuchs corneal endothelial dystrophy treated by corneal transplantation. Two patients had anterior synechiae, 1 had narrow-angle CTR Z capsular tension ring; IOL Z intraocular lens; PC IOL Z posterior chamber intraocular lens glaucoma, 1 had a history of retinal detachment and dry eye, and 1 had zonular dehiscence over the area of the iris defect.
Safety Outcomes
Safety outcomes for the modified CTR are shown in Table 2 . Two patients (12.5%) lost CDVA by 1 year after surgery. The first (patient 49) had a 1 Snellen line decrease in CDVA from 20/20 À2 to 20/25
À2
. She had preoperative corneal edema and CME from prior trauma and cataract surgery and was ultimately found to have changes consistent with age-related macular degeneration (AMD) at an examination 14 months after surgery. Her 1-line loss of CDVA was not considered attributable to the modified CTR. The second (patient 65) experienced a 2 Snellen line decrease from 20/15
À2 to 20/25 that was attributable to PCO. He experienced an improvement in CDVA to 20/15 and a reduction in glare symptoms after laser posterior capsulotomy. Two other patients (patients 62 and 64) had insignificant 1-to 2-letter decreases but also had PCO. Their CDVA improved after neodymium:YAG (Nd:YAG) laser capsulotomy. In all, there was only a 1-line loss of CDVA in 1 patient, which was not attributable to the modified CTR implantation. On the other hand, there was a statistically significant improvement in the median CDVA of 2.5 Snellen lines in all patients (P ! .01), including those who were already pseudophakic.
There were no intraoperative complications. Six patients had postoperative complications, 2 of which were device-related. The most common postoperative complication was elevated intraocular pressure (IOP), which occurred in 3 patients. Two of the patients were taking corticosteroids for CME before the start of the study. One of the patients (patient 22) was successfully treated with a glaucoma medication, and the other patient (patient 56) was managed by a medication change for his CME. An adverse event report was filed with the IRB in the latter case. The third patient (patient 58) with elevated IOP had a history of anterior synechiae. The modified CTR rotated after implantation in 2 patients. Patient 50 had a 15-degree rotation but did not complain of decreased visual acuity or glare symptoms and his iris defect was still well covered, so no additional surgery was performed. The other patient (patient 41) had a 25-degree rotation and was taken back to the operating room 1 week postoperatively for repositioning of the occluder paddle to the appropriate meridian, after which it remained in place. An adverse event report was filed in this case. Patient 56 developed a macula-off rhegmatogenous retinal detachment, which was managed by pars plana vitrectomy and scleral buckling. An adverse event report was filed for this event as well as his IOP rise, as mentioned previously. This patient had preoperative zonular dehiscence secondary to a penetrating injury. His CDVA at the 1-year follow-up was 20/40 C2 . Finally, patient 6 complained of glare sensitivity, and he developed a crescent-shaped negative dysphotopsia in the inferotemporal field of the eye with the CTR. This patient had implantation of an SN60AT IOL, a square-edge acrylic IOL that is known to cause negative dysphotopsia in a small percentage of cataract surgery patients. However, this did not affect his CDVA, which was 20/15 at the 1-year follow-up examination. None of the patients who had cataract surgery before modified CTR implantation experienced intraoperative or postoperative complications.
Altogether, there were 6 postoperative complications, 3 adverse event filings, and 4 secondary surgical interventions during the 1-year follow-up required by the study protocol. Two of the 4 secondary surgical interventions were laser capsulotomies. Several additional laser capsulotomies were performed more than 1 year after surgery.
Efficacy Outcomes
Efficacy outcomes for modified CTR implantation are shown in Table 3 . The change in CDVA with glare was statistically significant (P ! .01), with a median CDVA with glare improvement of 8 Snellen lines. All but 2 patients (patients 6 and 64) had an improvement in CDVA with glare; both of these patients were found to have PCO, and they subsequently had Nd:YAG laser capsulotomies. Patient 6 had a decrease from 20/40 À2 to less than 20/400 at the 1-year follow-up, but all follow-up examinations preceding 1 year showed a CDVA with glare of 20/15. After Nd:YAG laser posterior capsulotomy at 14 months, his precapsulotomy visual acuity was restored.
Daytime and nighttime glare improved significantly by a median of 5 points (P ! .01) and 4 points (P ! .01), respectively, on glare symptom grading. Both daytime and nighttime glare improved from median preoperative values of 9 to median postoperative values of 4. Almost every patient showed an improvement in the glare symptom score. Patient 10 had an C2 . This patient reported significant dry eye preoperatively. Patient 62 reported an increase in nighttime glare symptoms of 1 point, although she noted this was not an accurate assessment of her glare symptoms as she was experiencing other unrelated ocular issues that were negatively affecting her vision at the time her glare symptoms were scored.
Because cataract removal alone can reduce glare sensitivity, it is difficult to ascertain from these aggregate results how much reduction in glare was achieved by the modified CTR implantation. Four patients (overall study patients 49, 62, 64, and 65) were implanted with the modified CTR after they were pseudophakic. These patients experienced CDVA with glare improvements of 5, 3, 0, and more than 10 lines, respectively; subjective daytime glare score improvements of 10, 6, 6, and 5; and subjective nighttime glare score improvements of 4, À1, 2, and 5. Patients 62 and 64 developed PCO, which may explain some of their inconsistent efficacy results, and both patients subsequently had laser capsulotomies. These limited data, while insufficient for statistical analysis, support the hypothesis that implantation of the modified CTR independently reduces glare sensitivity beyond cataract surgery alone.
Overall, there was no statistically significant change in the subjective cosmetic appearance of eyes postoperatively, as one would expect with a black occluder device. Most patients reported no change in cosmetic appearance, but patient 13 reported a 5-point decrease from 9 to 4 and patient 5 reported a 9-point increase from 1 to 10. Patient 5 had significant iris reconstruction during his surgery. Patients 64 and 66 reported increases from 5 to 7 and from 3 to 7, respectively, although the reason for this improved subjective assessment is unclear.
DISCUSSION
The Morcher 96F iris diaphragm is a modified CTR with a 90-degree segmental occluder paddle that is made from black PMMA. It is intended for implantation in the capsular bag to relieve symptoms of light and glare sensitivity caused by small iris defects. Although used extensively in Europe and Asia, Morcher iris diaphragms are not FDA approved in the United States thus far and are no longer available by compassionate-use exemption. An IDE for this The primary safety measure of this study was the change in CDVA. Four patients lost between 1 letter and 2 lines of visual acuity to problems unrelated to device implantation, with 3 patients experiencing improvements in CDVA after laser posterior capsulotomy. There was a statistically significant improvement in CDVA at the 1-year postoperative follow-up visit for the group as a whole. This was expected because most of the patients in the study had visually significant cataracts preoperatively and had cataract extraction with IOL implantation at the time of the modified CTR implantation. The 4 patients (patients 49, 62, 64, and 65) who did not experience an improvement in CDVA were those who had cataract extraction with posterior chamber IOL placement before they enrolled in the study. Patient 49, the one who lost acuity for reasons other than PCO, had preoperative corneal edema and CME and shortly after the 1-year follow-up was found to have changes consistent with AMD. Her 1-line loss of CDVA was not attributable to the modified CTR.
Although most patients experienced improved CDVA, there were several who did not correct to 20/25 or better postoperatively. None of their outcomes were related to the modified CTR. Patients 5, 50, 64, and 66 were found to have PCO after cataract surgery and improved after Nd:YAG laser capsulotomy. Patient 52 had a history of Fuchs endothelial corneal dystrophy and corneal transplantation, and patient 56 had a complicated postoperative course with a macula-off retinal detachment, which was successfully repaired.
A theoretical concern with Morcher 96F implantation is low-grade toxicity from leakage of the black dye used in the manufacture of the device. Our FDAapproved protocol did not require the collection of corneal endothelial cell counts, fluorescein angiograms, or macular optical coherence tomograms. We obtained these studies only when indicated clinically dalmost always for ongoing evaluation of problems present before device implantation. Anecdotally, CDVA Z corrected distance visual acuity; CF Z counting fingers; CME Z cystoid macular edema; IOP Z intraocular pressure; PCO Z posterior capsule opacification; PPV Z pars plana vitrectomy; RD Z retinal detachment; SB Z scleral buckle *Measured 1 year postoperatively throughout the study we observed no clinical evidence of toxicity in any of our patients with a 96F CTR, nor have we found it in patients followed in other Morcher sub-studies. We have observed some patients for up to 10 years after implantation. Overall, the Morcher 96F device appears to be relatively safe. The 1 postoperative complication that is clearly related to device implantation is rotation of the occluder paddle. Fortunately, it is easy to remedy. We found no evidence of corneal or macular toxicity that we would attribute to the device. It is clear that the device does not negatively affect CDVA. Most of the postoperative complications seen in this study were unrelated to the device and easily managed with medications or reoperation. It is important to note that most cases of partial or complete aniridia in this study were due to trauma. As such, there is likely to be concomitant injury to other anterior segment structures in these patients, leading to preoperative ocular comorbidity or predisposing to postoperative complications. It is important for surgeons to be aware of the mechanism of the iris injury in traumatic cases and how this might affect surgical and perioperative management.
The primary efficacy measures of the study were objective changes in CDVA with glare and subjective changes in daytime and nighttime glare measurements. There was a statistically significant improvement in all 3 of these measures after modified CTR implantation. Only 2 patients (6 and 65) experienced a decrease in CDVA with glare; both had PCO that improved after laser posterior capsulotomy. All other patients improved to 20/30 or better postoperatively except for patients 5, 50, 52, and 56, probably for the same reasons discussed previously in regard to their CDVA measurements. Similarly, patients 22 and 66 only corrected to 20/50 and 20/40 postoperatively but were also found to have PCO and had subsequent laser capsulotomies.
Daytime and nighttime glare scores measured preoperatively and 3 months postoperatively improved in all but 2 patients. Both of these patients noted significant dry eye preoperatively and rated the dryness of their eyes as 8 or 9 out of 10, the highest scores in the study. Patient 62 also noted that she was experiencing several other unrelated problems at the time that were probably affecting her vision. Overall, Morcher 96F implantation proved to be effective in reducing glare and improving visual acuity in the presence of a glare source.
Cosmesis was evaluated subjectively, and there was no statistically significant impact of modified CTR implantation. This was expected because the device is black and difficult to distinguish from the preexisting irregular pupil or iris defect, thus having little to no impact on the external appearance of the eye. Patients who are candidates for artificial iris implantation who have cosmetic concerns with larger iris defects may prefer the Ophtec 311 or the Humanoptics artificial iris device, which are colored or hand-painted to match the fellow iris.
There are some surgical pearls we can share as we have gained considerable experience implanting Morcher devices. First, the 96F ring should never be implanted in the ciliary sulcus. It is not sized for this space and probably would rotate or jiggle if placed there. It must be inserted in the capsular bag. We have not found the device to be particularly brittle, although we have heard verbal anecdotes to this effect. To date, we have not broken a single device during implantation. Next, it is best to place the IOL in the capsular bag before placing the modified CTR. The open-loop portion of the device should be implanted first, followed by the occluder. It is harder to advance the occluder paddle around the capsular bag than the open-loop portion. Placing the modified CTR in front of the IOL should reduce the incidence of subjective temporal scotomas or negative dysphotopsias 16 that arise from the square edge of an IOL, especially when the occluder paddle is oriented nasally. It should also reduce the prominence of third and fourth Purkinje images. If a toric IOL is used, the ring may catch the optic-haptic junction and spin the IOL. The IOL may have to be repositioned after the occluder has been aligned with the iris defect. Next, as with any CTR, the ring should be advanced into the capsule in the direction of greatest zonular weakness to avoid stressing weak zonular fibers further. Last, we found it easiest to guide the occluder portion of the device into the capsular bag by advancing it with a Sinskey hook that had been placed through a positioning hole on the occluder while exerting inward and downward pressure on the outer edge of the device with a Kuglen or iris push-pull hook inserted through a paracentesis.
Because the cornea has a larger diameter than the capsular bag, some light will enter the eye around the periphery of the Morcher 96F if there is no residual iris tissue near the iris root. Still, the benefit is much greater than would be realized if no device were implanted. Unlike other artificial iris devices, the small size of the Morcher 96F allows for a much smaller surgical incision, leading to quicker healing and decreased surgical trauma to an eye that probably has suffered significant trauma already. We usually place a single 10-0 nylon suture to close the incision. Multiple devices can be implanted to cover larger iris defects, but the procedure becomes more difficult when the second device is implanted because of the volume of devices already in the capsular bag. If more area must be covered than is possible with 2 Morcher 96F rings, 2 Morcher 50F rings should be considered instead. The 50F device has 8 occluder paddles. It is possible to insert a 96F device into a pseudophakic eye, although this can be difficult if there is extensive capsule fibrosis. There are some minor aspects of the device that could be improved, such as the cosmesis of the implant, but overall the Morcher 96F has a proven beneficial role in the management of symptomatic congenital or traumatic aniridia and other defects of the iris.
In general, Morcher 96F device implantation is both safe and effective at relieving symptoms caused by small iris defects. The device is useful to prevent glare symptoms that might otherwise arise if the edge of an IOL were exposed to light coming in through an iris defect after implantation. Finally, the device is useful for treating small iris transillumination defects, such as those caused by iris prolapse through clear corneal incisions.
WHAT WAS KNOWN
Management of congenital and traumatic iris defects with iris diaphragms and iris reconstruction IOLs has been reported extensively throughout Europe and Asia with successful results in regard to safety and efficacy.
There have been few studies evaluating these devices in the United States because they are not FDA-approved and are no longer available through compassionate-use exemption.
WHAT THIS PAPER ADDS
The modified CTR was used safely to improve light sensitivity and glare symptoms in eyes with small iris defects.
